WO2017008388A1 - Biomarqueur des protéines pancréatiques, ses utilisations, puce de détection dudit biomarqueur, et dispositif de détection - Google Patents

Biomarqueur des protéines pancréatiques, ses utilisations, puce de détection dudit biomarqueur, et dispositif de détection Download PDF

Info

Publication number
WO2017008388A1
WO2017008388A1 PCT/CN2015/089892 CN2015089892W WO2017008388A1 WO 2017008388 A1 WO2017008388 A1 WO 2017008388A1 CN 2015089892 W CN2015089892 W CN 2015089892W WO 2017008388 A1 WO2017008388 A1 WO 2017008388A1
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic cancer
monoclonal antibody
icam
opg
detection
Prior art date
Application number
PCT/CN2015/089892
Other languages
English (en)
Chinese (zh)
Inventor
张贯京
普拉纽克克里斯基捏
古列莎艾琳娜
波达别特伊万
Original Assignee
深圳市华科安测信息技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市华科安测信息技术有限公司 filed Critical 深圳市华科安测信息技术有限公司
Publication of WO2017008388A1 publication Critical patent/WO2017008388A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Definitions

  • the invention belongs to the technical field of biological detection, and particularly relates to a pancreatic cancer protein biomarker, a use thereof, a detection chip thereof and a detection device.
  • Pancreatic cancer is a malignant tumor of the digestive tract with a high degree of malignancy and is difficult to diagnose and treat. About 90% of ductal adenocarcinomas originate from the ductal epithelium. Usually after onset, the 5-year survival rate is ⁇ 1%, which is one of the worst prognosis.
  • pancreatic cancer The important reason for the low prognosis of pancreatic cancer is that there is no symptom in the early stage of pancreatic cancer, and it is difficult to detect it during the incubation period or initial stage of pancreatic cancer, thus delaying the optimal treatment time. It is mainly difficult to be detected because there is no symptom at the beginning of the disease, and there is a certain positive rate when there is no detection of CA19-9, CEA, CA242 pancreatic cancer detection markers with the best detection accuracy. High specificity. According to statistics, the use of the above markers in the detection of pancreatic cancer during pregnancy (before canceration) is less sensitive, such as 1 year before the onset, 68% sensitivity, two years before the onset, the sensitivity is 53%. The use of other routine clinical techniques, such as B-ultrasound, CT, MRI, ERCP, PTCD, angiography, laparoscopic examination, etc., found that cancer has been in the advanced stage of cancer, greatly delaying the diagnosis and treatment.
  • the object of the present invention is to overcome the above-mentioned deficiencies of the prior art, and to provide a pancreatic cancer protein biomarker, a use thereof, a detection chip thereof and a detection device capable of better accuracy and specificity.
  • a pancreatic cancer protein biomarker comprising CRP, ICAM-1, OPG and CA19-9 stably present and detectable in human serum/plasma.
  • pancreatic oncoprotein biomarker of the present invention is screened by means of "differential subtraction method", that is, the normal sample is used as a control, and the whole protein in the normal sample is deducted from the cancerous sample, and the extra part is a regulatory protein specific to cancer. Verification shows that it is involved in the development of pancreatic cancer and is a credible early biomarker for pancreatic cancer, which has higher specificity and sensitivity than existing detection markers.
  • the present invention further provides the use of the above pancreatic cancer protein biomarkers in a pancreatic cancer detecting device.
  • the pancreatic cancer protein biomarker of the present invention is used as a basic pancreatic cancer detecting device, and the detected target is a differential analysis method to screen the above marker protein, which has higher specificity and sensitivity than the existing detection marker. .
  • the present invention further provides a detection chip for a pancreatic cancer protein biomarker, comprising a solid phase matrix, and CRP monoclonal antibody, ICAM-1 monoclonal antibody, OPG monoclonal antibody and CA19-9 immobilized on the solid phase substrate.
  • a detection chip for a pancreatic cancer protein biomarker comprising a solid phase matrix, and CRP monoclonal antibody, ICAM-1 monoclonal antibody, OPG monoclonal antibody and CA19-9 immobilized on the solid phase substrate.
  • Monoclonal antibody Monoclonal antibody.
  • the present invention also proposes a detecting device comprising the above-described pancreatic cancer protein biomarker detection chip.
  • the detection chip and the detection device of the present invention are prepared by immunizing CRP, ICAM-1, OPG and CA19-9 with specific CRP monoclonal antibody, ICAM-1 monoclonal antibody, OPG monoclonal antibody and CA19-9 monoclonal antibody, and the antigen is passed through the antigen. - Specific binding of antibodies to detect the above biomarker proteins with relatively high accuracy and specificity.
  • FIG. 1 is a schematic view showing the arrangement of spotting holes on a solid phase substrate in a chip according to an embodiment of the present invention
  • FIG. 2 is a schematic view showing the overall shape of a pancreatic cancer protein biomarker after the detection chip is packaged according to an embodiment of the present invention.
  • the present invention provides a pancreatic cancer protein biomarker comprising CRP (C-reactive protein), ICAM-1 (intercellular adhesion molecule-1), OPG (osteoprotegerin) and CA19-9 (sugar chain antigen 19-9) .
  • the present invention proposes the above biomarkers based on the detection and examination of pancreatic cancer, and the markers of the present invention are more accurate than the conventional clinical analysis means and the commonly used CA19-9, CEA, CA242 pancreatic cancer detection markers.
  • the discovery and presentation of the above-described combination of biomarkers of the present invention is based on the fact that the biomarker itself is a measurable indicator reflecting the presence and state of the disease, and any physiological changes in the course of disease, stress and recovery can ultimately It is the most intuitive means of disease research at the protein level; and multiple protein biomarker groups are closely related to the clinical and prognosis of patients with chronic diseases, indicating that simultaneous detection of multiple protein factors contributes to a more comprehensive understanding of the disease. process.
  • the protein in the above-mentioned biomarker combination belongs to a regulatory protein peculiar to a disease. Because tissue fluids, such as plasma, have thousands of protein species and concentration ranges up to 1010, the most advanced instruments can only measure a concentration range of 103; to overcome the interference of healthy background proteins on disease-specific protein.
  • the above marker proteins were screened by differential analysis and verified. The specific screening process is as follows:
  • a total of 210 subjects with known physical conditions were selected, including 55 healthy controls, 65 patients with initial pancreatic cancer (not metastasized), and 90 patients with metastatic pancreatic cancer. (This study has been approved by an ethics review agency and all subjects have signed informed consent.)
  • the most advanced instruments can only measure the concentration range span 103; currently, antibodies are used to remove 20 to 100 high-abundance proteins in the sample.
  • the detection rate of low-abundance proteins is increased, when compared with more than 1000 proteins in plasma, the residual relatively high-abundance protein has a ng concentration on the markers used in cancer and cancer-related developmental gestation-related markers.
  • the analysis signal of the pg concentration still has a severe flooding effect.
  • the present invention adopts a subtractive subtraction technique, and uses a healthy control plasma sample as an antigen to immunize a rabbit, and prepares a polyclonal antibody against a healthy control plasma protein, and uses the antibody as an affinity adsorption medium to prepare a chromatography column.
  • a large number of health-related proteins in patient plasma samples are specifically adsorbed and removed to obtain as much disease-related as possible, excluding interference from health-related high-abundance proteins.
  • low-abundance differentially expressed proteins were analyzed and detected by SDS-PAGE and mass spectrometry after removing a large amount of background interference from high-abundance proteins and enriching the amount.
  • the healthy control group In the early screening stage, the healthy control group, the initial stage of pancreatic cancer (not metastasized), and the patients with metastatic pancreatic cancer were identified by mass spectrometry, and the protein was identified three times in each of the three replicates of each group, and 210, 320, and 378 proteins were identified. protein.
  • the present invention aims to find early biomarkers of pancreatic cancer, which are only found in patients with initial pancreatic cancer (untransferred) and metastatic pancreatic cancer, but there are 45 proteins that are not present in healthy controls. There were 179 proteins in healthy controls, early pancreatic cancer patients (not metastasized), and patients with metastatic pancreatic cancer. This trial is aimed at the analysis of only 45 proteins co-occurring in patients with early stage pancreatic cancer (no metastasis) and metastatic pancreatic cancer.
  • CRP C-reactive protein
  • ICAM-1 intercellular adhesion molecule-1
  • OPG osteoprotegerin
  • CA19-9 CA19-9 in the pancreatic cancer group.
  • the amount is significantly higher than the healthy control and increases as the patient's condition is severe (increased proteinuria).
  • the relative content of these four protein markers was determined by reference to the normal range and the cutoff values of the four protein molecules to determine the relative content of the four protein markers.
  • the various combinations were statistically processed to compare the sensitivity and specificity of the different combinations. The results are shown in Table 3 below. Among them, in the combination indicated by the symbol " ⁇ " in Table 3, sensitivity and specificity were calculated when all the biomarkers contained in the combination were positive (i.e., higher than the cutoff value). In the combination indicated by the symbol " ⁇ ", when one of the biomarkers contained in the combination is positive, it is judged to be positive, and the sensitivity and specificity are calculated.
  • the present invention proposes the above four biomarker proteins for use in a detection device for pancreatic cancer. Detecting device determined as described above The four biomarker proteins are used as the basis for the corresponding biochemical detection, and their application has higher specificity and sensitivity than the existing detection methods and methods compared with other existing detection methods and means.
  • the invention further provides a detection chip for a pancreatic cancer protein biomarker based on the combination of the above pancreatic cancer protein biomarker, the detection chip comprises: a solid phase carrier, and a CRP monoclonal antibody immobilized on the solid phase carrier, ICAM- 1 mAb, OPG mAb and CA19-9 mAb.
  • the detection chip of the pancreatic cancer protein biomarker of the present invention by immobilizing the monoclonal antibody of the above protein biomarker on a solid phase carrier, and capturing the protein to be tested which can specifically bind thereto by the corresponding monoclonal antibody, thereby realizing Separation of the target marker protein in serum, plasma, lymph, interstitial fluid, urine, exudate, cell lysate, and secretion sample waiting for the sample; followed by washing, purification, confirmation, and biochemical analysis; The differential expression results of these biomarker proteins in the sample to be tested are obtained.
  • the monoclonal antibody of the four biomarker proteins contained in the detection chip of the pancreatic cancer protein biomarker is used in the present invention to immunize a monoclonal antibody by using the rabbit as an immunogen, for example, the preparation of CRP monoclonal antibody is Examples include:
  • CRP protein was used as an antigen to enter the peripheral immune organs of rabbits through blood circulation or lymphatic circulation, and the corresponding B lymphocyte clones were stimulated and activated. Proliferate and differentiate into sensitized B lymphocytes;
  • the rabbit When the immunization reaches the target level, the rabbit is sacrificed, and the spleen of the rabbit is taken; after the fine crushing, the single cell suspension is digested by enzymatic digestion, and the cell fusion hybridization is performed with the tumor cells;
  • the successful fusion cell dilution method is used for cloning and culture of hybrid cells; after culture, positive hybridoma cells capable of producing monoclonal antibodies against CRP protein are screened by immunization method; and the positive hybridoma cells are cultured in vitro. In the process of culture, the expression is induced at the appropriate time, and after the completion of the culture, the CRP monoclonal antibody can be obtained.
  • CRP monoclonal antibody, ICAM-1 monoclonal antibody, OPG monoclonal antibody and CA19-9 monoclonal antibody are separately prepared, and then fixed to a solid phase carrier by covalent crosslinking or non-covalent crosslinking.
  • the solid phase carrier as a protein chip in practice can generally be selected from a nitrocellulose membrane, a nylon membrane, a gold membrane, a flat plate or a glass substrate.
  • a nitrocellulose membrane or a glass substrate is preferably used for the purpose of performing low-abundance differential protein-specific adsorption for the above-mentioned monoclonal antibody. The reason is that the nitrocellulose membrane itself is a permeation membrane, and the nitrocellulose cellulose microporous membrane has a large capacity for an empty structure and a strong binding force to proteins.
  • the use of a glass substrate is mainly convenient, inexpensive, easy to handle, and has sufficient stability and inertness, and is very suitable for large-scale commercial production of the product of the present invention.
  • the glass substrate needs to be treated according to the characteristics of the present invention, because the glass substrate as the protein carrier is a glass plate, and the surface hydroxyl group is firstly used with N,N-diethoxyaminopropyltriethoxylate.
  • the silane is surface-treated; then the antibody protein is coupled, but the glass substrate has a very strong non-specific adsorption, which is likely to cause very serious background interference, especially in the above four kinds of target proteins to be detected in the present invention.
  • the glass substrate is used as a solid phase carrier in the present invention
  • the glass substrate is surface-treated with PEG (polyethylene glycol), and the surface treated with PEG has better signal intensity than the siliconized surface, and the macromolecular analysis component can be improved
  • PEG polyethylene glycol
  • the ability to bind to a ligand, such as a ligand, can attenuate non-specific binding; this is because PEG has a large spatial structure, which reduces the steric hindrance between proteins and can increase the specificity of affinity adsorption.
  • a positive control and a negative control are also immobilized on the above-mentioned protein chip of the present invention.
  • the positive control can use IgG monoclonal antibody, and the positive control IgG monoclonal antibody is preferably prepared by using the same immune body as above.
  • the positive control is prepared by using rabbit as an immunogen, then the IgG monoclonal antibody is also the best. It is prepared by using rabbit as an immunological body; the positive control is used to detect the binding of the target protein.
  • the negative control can use a sample-like dilution of the sample, which does not contain any bindable protein, just as a blank control.
  • the solid phase carrier of the above-mentioned protein chip of the present invention is provided with spotting holes, and the spotting holes may be disposed on the surface of the solid phase carrier in a matrix or array manner.
  • the corresponding monoclonal antibodies used to detect the biomarker protein are then immobilized in these spotted wells.
  • the structure of the sampled hole is used for operation detection.
  • the protein in the sample hole can be well separated, and the cross-contamination is minimized; on the other hand, the concave structure of the hole can facilitate the addition and preservation of the spotting buffer.
  • the rules and sizes of the spotting holes can be standardized, which facilitates horizontal comparison of the amount of spotting. Controlling the amount of sample is also more conducive to lateral comparison and calculation of results.
  • the present invention also provides a detection kit for a pancreatic cancer protein biomarker for the purpose of specifically detecting the above-mentioned pancreatic cancer protein organism for the convenience of the detection chip of the pancreatic cancer protein biomarker described above.
  • the above four monoclonal antibodies are respectively used as a chromatographic medium to form a chromatography column, and then the sample to be tested is subjected to a column, and then assisted by electrophoresis, mass spectrometry and the like.
  • the enzyme-labeled antigen may be used, and the sample protein to be tested is subjected to an enzyme labeling, and then subjected to an affinity reaction with the above-mentioned four monoclonal antibodies, and then the signal is detected by the enzyme-labeled antigen bound to the respective monoclonal antibody.
  • the kit of the present invention refers to the double-anti-sandwich method to assist the auxiliary reagent, and further, the auxiliary reagent includes the sample dilution buffer.
  • a 30-70 mM PBS phosphate buffer containing 1.5% to 2% BSA (bovine serum albumin) stabilizer is used as the sample dilution buffer; the sample dilution buffer is used for sample dilution and washing, wherein BSA It is a protein stabilizer that prevents protein breakdown and non-specific adsorption; and BSA also mitigates some adverse environmental factors such as heat, surface tension and chemical factors, thereby reducing the denaturation of some proteins during the test.
  • BSA bovine serum albumin
  • the above kit of the present invention further needs to cooperate with the enzyme-labeled secondary antibody according to the principle of the double-anti-sandwich method; after the sample to be tested, each protein of interest will be It is captured by the corresponding monoclonal antibody and affinity-adsorbed. At this time, an excess of the enzyme-labeled secondary antibody is added to bind to the target protein to form a sandwich structure; then the amount of the enzyme-labeled secondary antibody can be reacted in the sample to be tested.
  • the expression of the target protein can be obtained by calculating the signal carried by the enzyme-labeled secondary antibody.
  • the above-mentioned enzyme-labeled secondary antibody can be carried out by using a relatively common HRP (horseradish peroxidase)-containing enzyme-labeled secondary antibody, and in the case of satisfying the accuracy, the self-designed and manufactured product is also omitted. trouble.
  • HRP horseradish peroxidase
  • the kit may further comprise a concentrated washing solution containing 1 ⁇ 2%. BSA, 0.03 ⁇ 0.07% Tween-20 PBS, used to concentrate the enzyme-labeled secondary antibody and signal detection color components.
  • BSA 0.03 ⁇ 0.07% Tween-20 PBS
  • TMB tetramethylbenzidine
  • a solid phase matrix can also be provided in the kit, which in practice is a matrix similar to the above-mentioned chip, functioning as a carrier and a reaction medium.
  • the specific shape and morphology can also be referred to in the above description of the chip.
  • the corresponding monoclonal antibody is fixed to the spotting hole of the solid phase matrix according to the instructions of the kit manual, and then the detection of the sample to be tested is performed;
  • the solid phase matrix carrier is not provided in the kit of the present invention, it can also be carried out by using a spotting plate of the ELISA kit.
  • kits for the setting of the comparison, refer to the description in the above chip, and the usage is the same as the sample to be tested, and the operation is performed synchronously with the sample to be tested, and then the results are compared to provide a comparative reference.
  • the present invention also proposes a pancreatic cancer detecting device apparatus including the above detection chip.
  • the above chip and the device for detecting the chip signal such as a CCD detector, may be combined with similar detection signal devices; or the chip may be directly fixed in the detection port of the detection to form a whole.
  • the detection device device of the invention comprising the detection chip, the detection chip is made into a whole device capable of directly detecting the biomarker protein completely, and the biomarker protein is detected by the specific binding of the antigen-antibody, which is relatively high. Accuracy and specificity.
  • Example 1 is used to demonstrate the accuracy of pancreatic cancer detection using the above-described biomarkers of the present invention and the authenticity of the test results using the kit.
  • a 50 mM pH 7 containing 2% BSA was added dropwise to the spotted well. .2
  • the PBS buffer solution was then incubated with a cover slip for 2 h; the front and back surfaces of the slides blocked with BSA were washed three to four times with 50 mM pH PBS buffer solution and allowed to air dry.
  • a developer TMB (tetramethylbenzidine) substrate liquid matched with the enzyme standard working solution is added to the reaction area of the chip, and 20 ul per well is added for chemiluminescence.
  • the above biomarker proteins of 500 subjects were detected.
  • the results of the test showed that 24 subjects were treated according to the combination category of Table 3 above.
  • the patients were judged to be suspected of pancreatic cancer; the 24 abnormal subjects were further followed up and re-clinical and comprehensive symptom analysis were performed within the next six months.
  • the results showed that 22 of 24 people were diagnosed with pancreatic cancer (of which 6 were of type that had spread, 16 of which were of initial non-proliferation type), and the remaining 2 were not considered to be pancreatic cancer patients, but Other interfering conditions.
  • the detection kit for the above-mentioned markers of the present invention is based on the double-anti-sandwich method, and the detection of the affinity antibody for detecting the above biomarker is carried out, and the detection accuracy has high accuracy and sensitivity. . Moreover, compared with the current CA19-9, CEA, CA242 pancreatic cancer detection markers, it can cover the early stage of pancreatic cancer and not miss the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne un biomarqueur protéique du cancer du pancréas et ses applications. Le marqueur comprend les protéines CRP, ICAM-1, OPG, et CA19-9 détectables à l'état stable dans le plasma/sérum humain. Le biomarqueur des protéines pancréatiques est acquis au moyen d'un criblage faisant appel à une recherche de différence de faible abondance, s'avère participer au développement et à la progression du cancer du pancréas, est un biomarqueur de stade précoce crédible du cancer du pancréas, et fait preuve d'une spécificité et d'une sensibilité accrues comparativement à un marqueur de détection existant. Sur cette base, une puce de détection pour biomarqueur protéique du cancer du pancréas et un appareil de détection la comprenant sont en outre décrits. La puce de détection est fixée à un substrat en phase solide pour former une puce basée sur un anticorps monoclonal anti-CRP, un anticorps monoclonal anti-ICAM-1, un anticorps monoclonal anti-OPG, et un anticorps monoclonal anti-CA19-9 spécifiques ; détecte les protéines du biomarqueur au moyen de la combinaison de spécificité antigène-anticorps ; et fait preuve d'une précision et d'une spécificité accrues.
PCT/CN2015/089892 2015-07-10 2015-09-17 Biomarqueur des protéines pancréatiques, ses utilisations, puce de détection dudit biomarqueur, et dispositif de détection WO2017008388A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510408299.9A CN105092845A (zh) 2015-07-10 2015-07-10 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置
CN201510408299.9 2015-07-10

Publications (1)

Publication Number Publication Date
WO2017008388A1 true WO2017008388A1 (fr) 2017-01-19

Family

ID=54573749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/089892 WO2017008388A1 (fr) 2015-07-10 2015-09-17 Biomarqueur des protéines pancréatiques, ses utilisations, puce de détection dudit biomarqueur, et dispositif de détection

Country Status (2)

Country Link
CN (1) CN105092845A (fr)
WO (1) WO2017008388A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110716058A (zh) * 2019-11-19 2020-01-21 杭州纽蓝科技有限公司 一种超敏c反应蛋白检测用芯片
WO2022013385A1 (fr) * 2020-07-16 2022-01-20 Immunovia Ab Méthodes, jeux ordonnés d'échantillons et leurs utilisations
US11525832B2 (en) 2007-03-27 2022-12-13 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105092844A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物的检测试剂盒及检测系统
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
CN114235990A (zh) * 2021-11-29 2022-03-25 宁夏医科大学 一种结核病血清标志物筛选方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105092844A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物的检测试剂盒及检测系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
CN101603966A (zh) * 2008-06-12 2009-12-16 上海裕隆生物科技有限公司 一种男性多肿瘤标志物检测蛋白芯片及其试剂盒
CN101993913A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种icam1基因的原位杂交检测试剂盒及其检测方法和应用
CN104764885B (zh) * 2015-03-24 2016-08-24 深圳市贝沃德克生物技术研究院有限公司 糖尿病肾病早期筛查试剂盒、生物标志物检测方法及应用
CN104764886B (zh) * 2015-03-24 2016-08-24 深圳市贝沃德克生物技术研究院有限公司 糖尿病肾病早期检测试纸盒、生物标志物检测方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105092844A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物的检测试剂盒及检测系统

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAND, R.E. ET AL.: "Serum Biomarker Panels for the Detection of Pancreatic Cancer", CLINICAL CANCER RESEARCH, vol. 17, no. 4, 15 February 2011 (2011-02-15), pages 805 - 817, XP055195019, ISSN: 1078-0432 *
ZHANG, PENGJUN ET AL.: "Development of Serum Parameters Panels for the Early Detection of Pancreatic Cancer", INTERNATIONAL JOURNAL OF CANCER, 7 November 2013 (2013-11-07), pages 2646 - 2655, XP055345282 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11525832B2 (en) 2007-03-27 2022-12-13 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
CN110716058A (zh) * 2019-11-19 2020-01-21 杭州纽蓝科技有限公司 一种超敏c反应蛋白检测用芯片
WO2022013385A1 (fr) * 2020-07-16 2022-01-20 Immunovia Ab Méthodes, jeux ordonnés d'échantillons et leurs utilisations
US11320436B2 (en) 2020-07-16 2022-05-03 Immunovia Ab Methods, arrays and uses thereof

Also Published As

Publication number Publication date
CN105092845A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
Caza et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy
WO2017008388A1 (fr) Biomarqueur des protéines pancréatiques, ses utilisations, puce de détection dudit biomarqueur, et dispositif de détection
WO2017008389A1 (fr) Kit de réactifs de réaction et système de détection de biomarqueurs protéiques du cancer du pancréas
WO2019148753A1 (fr) Bandelette réactive et procédé de test d'anticorps thsd7a
EP2431391B1 (fr) Anticorps monoclonal pour l'analyse de l'adiponectine de masse moléculaire élevée et son utilisation
CN113248609B (zh) 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
KR101219519B1 (ko) 렉틴을 이용한 암 진단 방법
WO2005043165A2 (fr) Methode specifique de detection du cancer
EP3859332B1 (fr) Procédé de dosage d'hémoglobine glyquée (%)
Zhang et al. Glyco-CPLL: an integrated method for in-depth and comprehensive N-glycoproteome profiling of human plasma
US20200408763A1 (en) Novel stool-based protein biomarkers for colorectal cancer screening
Abdalla et al. Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients
KR20150061816A (ko) 혈액유래 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법
Hsiao et al. Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry
CN110687283A (zh) 自身抗体在诊断和/或治疗肿瘤中的应用
KR20110038778A (ko) 다중렉틴을 이용한 체액 유래 단백질 동정 방법 및 이 방법에 의하여 탐지된 간암 바이오마커
WO2013187371A1 (fr) Méthode pour la détection du cancer, et anticorps apte à reconnaître la ribonucléase 1 spécifique du pancréas
WO2017008380A1 (fr) Procédé d'isolement d'une protéine par différence de faible abondance et ses applications
WO2011099435A1 (fr) PROCÉDÉ DE MESURE DE L'IMMUNITÉ DU COMPLEXE ASSOCIANT Ku86 ET UN DE SES AUTO-ANTICORPS, NÉCESSAIRE UTILISÉ À CET EFFET ET MÉTHODE DE DIAGNOSTIC DU CANCER L'UTILISANT
Hardouin et al. Usefulness of autoantigens depletion to detect autoantibody signatures by multiple affinity protein profiling
WO2022023461A1 (fr) Épitope amélioré pour la détection et/ou la quantification d'auto-anticorps contre l'alpha-fœtoprotéine
KR20110129508A (ko) 폐암 바이오마커
US20230018242A1 (en) Kit of in vitro quantifying large surface protein of hepatitis b virus (hbv), biomarker set for analyzing phases of hbv infection and hepatoma prognosis, and set of monoclonal antibodies for predicting, diagnosing or treating chronic liver disease
Cui et al. A Rapid and Highly Sensitive Chemiluminescent Method to Quantify HPV16E7 Antibody Based on Immunomagnetic Separation Methods.
Zhang et al. Research Progress on Quantification Methods of Drug Concentration of Monoclonal Antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15898115

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15898115

Country of ref document: EP

Kind code of ref document: A1